CA2223760C - Procede de determination de taux de consommation d'alcool - Google Patents
Procede de determination de taux de consommation d'alcool Download PDFInfo
- Publication number
- CA2223760C CA2223760C CA002223760A CA2223760A CA2223760C CA 2223760 C CA2223760 C CA 2223760C CA 002223760 A CA002223760 A CA 002223760A CA 2223760 A CA2223760 A CA 2223760A CA 2223760 C CA2223760 C CA 2223760C
- Authority
- CA
- Canada
- Prior art keywords
- panel
- constituent
- alcohol
- consumption
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 119
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 105
- 239000000470 constituent Substances 0.000 claims abstract description 106
- 210000004369 blood Anatomy 0.000 claims abstract description 44
- 239000008280 blood Substances 0.000 claims abstract description 44
- 238000004458 analytical method Methods 0.000 claims abstract description 37
- 238000012360 testing method Methods 0.000 claims description 73
- 208000007848 Alcoholism Diseases 0.000 claims description 25
- 201000007930 alcohol dependence Diseases 0.000 claims description 23
- 238000008789 Direct Bilirubin Methods 0.000 claims description 19
- 238000008050 Total Bilirubin Reagent Methods 0.000 claims description 16
- 238000007477 logistic regression Methods 0.000 claims description 15
- 102000001554 Hemoglobins Human genes 0.000 claims description 12
- 108010054147 Hemoglobins Proteins 0.000 claims description 12
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 12
- 229910052711 selenium Inorganic materials 0.000 claims description 12
- 239000011669 selenium Substances 0.000 claims description 12
- 238000007619 statistical method Methods 0.000 claims description 11
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 6
- 230000011514 reflex Effects 0.000 claims description 6
- 206010013710 Drug interaction Diseases 0.000 claims description 5
- 230000037213 diet Effects 0.000 claims description 5
- 235000005911 diet Nutrition 0.000 claims description 5
- 238000007621 cluster analysis Methods 0.000 claims description 4
- 238000000556 factor analysis Methods 0.000 claims description 4
- 108700022763 carbohydrate-deficient transferrin Proteins 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 230000006855 networking Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 238000013179 statistical model Methods 0.000 abstract description 3
- 238000012986 modification Methods 0.000 abstract description 2
- 230000004048 modification Effects 0.000 abstract description 2
- 230000035622 drinking Effects 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 28
- 238000010200 validation analysis Methods 0.000 description 25
- 238000009533 lab test Methods 0.000 description 20
- 230000035945 sensitivity Effects 0.000 description 15
- 108010010234 HDL Lipoproteins Proteins 0.000 description 12
- 102000015779 HDL Lipoproteins Human genes 0.000 description 12
- 238000012549 training Methods 0.000 description 12
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000011777 magnesium Substances 0.000 description 10
- 229910052749 magnesium Inorganic materials 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 239000010949 copper Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 229910052802 copper Inorganic materials 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000011701 zinc Substances 0.000 description 7
- 229910052725 zinc Inorganic materials 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 230000001476 alcoholic effect Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 230000000391 smoking effect Effects 0.000 description 5
- 201000009032 substance abuse Diseases 0.000 description 5
- 208000011117 substance-related disease Diseases 0.000 description 5
- -1 3-hexacosanamine Chemical compound 0.000 description 4
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 4
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 4
- 230000002489 hematologic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000736 substance abuse Toxicity 0.000 description 3
- 244000202285 Acrocomia mexicana Species 0.000 description 2
- 235000003625 Acrocomia mexicana Nutrition 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 101100257137 Caenorhabditis elegans sma-6 gene Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 108010075016 Ceruloplasmin Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010039921 Selenium deficiency Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 238000007473 univariate analysis Methods 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
- 101150011812 AADAC gene Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 235000009581 Balanites aegyptiaca Nutrition 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 208000010152 Huntington disease-like 3 Diseases 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102100039133 Integrator complex subunit 6 Human genes 0.000 description 1
- 101150014481 Ints6 gene Proteins 0.000 description 1
- 201000002772 Kwashiorkor Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000252067 Megalops atlanticus Species 0.000 description 1
- 101100161696 Myxine glutinosa ache gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 102220011105 rs201352584 Human genes 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Procédé permettant d'évaluer des taux de consommation d'alcool consistant, entre autres, à utiliser un échantillon de sang d'un sujet humain pour mettre au point un tableau individuel de constituants du sang, à comparer ledit tableau individuel avec un tableau de constituants du sang de référence pour obtenir des catégories correspondant à des taux de consommation d'alcool, et à identifier la catégorie de taux de consommation. On peut varier les procédés de l'invention en modifiant un ou plusieurs modèles statistiques utilisés conjointement avec ceux-ci pour pondérer de manière préférentielle l'analyse et identifier une catégorie de consommation donnée par rapport à une autre. Des techniques multidimensionnelles et autres techniques statistiques similaires corrèlent des comparaisons de fractions de tableaux sanguins d'individus/de sujets et de référence avec des taux de consommation reconnus.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/481,656 US5798267A (en) | 1994-07-14 | 1995-06-07 | Method for determining alcohol consumption rates |
| US08/481,656 | 1995-06-07 | ||
| PCT/US1996/009898 WO1996041199A1 (fr) | 1995-06-07 | 1996-06-07 | Procede de determination de taux de consommation d'alcool |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2223760A1 CA2223760A1 (fr) | 1996-12-19 |
| CA2223760C true CA2223760C (fr) | 2006-07-04 |
Family
ID=36648512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002223760A Expired - Fee Related CA2223760C (fr) | 1995-06-07 | 1996-06-07 | Procede de determination de taux de consommation d'alcool |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2223760C (fr) |
-
1996
- 1996-06-07 CA CA002223760A patent/CA2223760C/fr not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2223760A1 (fr) | 1996-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ambwani et al. | Socially desirable responding by bariatric surgery candidates during psychological assessment | |
| Saunders et al. | Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption‐II | |
| Barr et al. | Urinary creatinine concentrations in the US population: implications for urinary biologic monitoring measurements | |
| Aertgeerts et al. | The value of the CAGE in screening for alcohol abuse and alcohol dependence in general clinical populations: a diagnostic meta-analysis | |
| Schnurr et al. | Combat exposure, posttraumatic stress disorder symptoms, and health behaviors as predictors of self-reported physical health in older veterans | |
| Shaw et al. | Diabetic neuropathy in Mauritius: prevalence and risk factors | |
| Nylen et al. | Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome | |
| Dalton et al. | Mind and cancer: do psychological factors cause cancer? | |
| Wurst et al. | Measurement of direct ethanol metabolites suggests higher rate of alcohol use among pregnant women than found with the AUDIT—a pilot study in a population-based sample of Swedish women | |
| Batty et al. | Pre-morbid intelligence, the metabolic syndrome and mortality: the Vietnam Experience Study | |
| Hillier et al. | Practical way to assess metabolic syndrome using a continuous score obtained from principal components analysis: The DESIR Cohort | |
| Lacher et al. | Biological variation of laboratory analytes based on the 1999-2002 National Health and Nutrition Examination Survey | |
| Tavakoli et al. | Review of current clinical biomarkers for the detection of alcohol dependence | |
| JP2001511680A (ja) | 将来の健康を予測するためのシステム | |
| JP2009535644A (ja) | バイオマーカーを使用して疾患状況を同定するための方法および装置 | |
| Harasymiw et al. | Identification of heavy drinkers by using the early detection of alcohol consumption score | |
| Foy et al. | Data‐driven physiologic thresholds for iron deficiency associated with hematologic decline | |
| EP0852013B1 (fr) | Procede de determination de taux de consommation d'alcool | |
| CA2223760C (fr) | Procede de determination de taux de consommation d'alcool | |
| Hadaegh et al. | The metabolic syndrome and incident diabetes: Assessment of alternative definitions of the metabolic syndrome in an Iranian urban population | |
| Cervera-Enguix et al. | The development and validation of a Spanish version of the quality of life in depression scale (QLDS) | |
| US5126271A (en) | Method for determining the consumption rate of alcohol by a human subject | |
| WHITFIELD et al. | A multivariate assessment of alcohol consumption | |
| Thiesen et al. | Biological markers of problem drinking in homeless patients | |
| US5823196A (en) | Method for detecting alcohol consumption rates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160607 |